X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (26) 26
humans (22) 22
index medicus (19) 19
lung cancer (15) 15
male (12) 12
chemotherapy (11) 11
female (11) 11
aged (10) 10
cancer (10) 10
carcinoma, non-small-cell lung - genetics (10) 10
lung neoplasms - genetics (10) 10
middle aged (10) 10
mutation (10) 10
antineoplastic agents - therapeutic use (9) 9
lung neoplasms - drug therapy (9) 9
survival (9) 9
carcinoma, non-small-cell lung - drug therapy (8) 8
gefitinib (8) 8
lung cancer, non-small cell (7) 7
medicine & public health (7) 7
quinazolines - therapeutic use (7) 7
treatment outcome (7) 7
adenocarcinoma (6) 6
aged, 80 and over (6) 6
care and treatment (6) 6
open-label (6) 6
protein kinase inhibitors - therapeutic use (6) 6
receptor, epidermal growth factor - genetics (6) 6
adult (5) 5
disease-free survival (5) 5
egfr (5) 5
erlotinib hydrochloride (5) 5
lung neoplasms - pathology (5) 5
non-small cell lung cancer (5) 5
non-small cell lung carcinoma (5) 5
respiratory tract diseases (5) 5
tumors (5) 5
acquired-resistance (4) 4
antineoplastic agents - adverse effects (4) 4
apoptosis (4) 4
cancer therapies (4) 4
carcinoma, non-small-cell lung - pathology (4) 4
cisplatin (4) 4
erlotinib (4) 4
genetic aspects (4) 4
kaplan-meier estimate (4) 4
mutations (4) 4
original (4) 4
prospective studies (4) 4
quinazolines - adverse effects (4) 4
respiratory system (4) 4
therapy (4) 4
tyrosine kinase inhibitor (4) 4
1st-line treatment (3) 3
abridged index medicus (3) 3
animals (3) 3
cancer research (3) 3
carcinoma, non-small-cell lung - mortality (3) 3
cell lung-cancer (3) 3
clinical trials (3) 3
crizotinib (3) 3
diagnosis (3) 3
dna repair - genetics (3) 3
gender (3) 3
gene-mutations (3) 3
growth-factor-receptor (3) 3
immunotherapy (3) 3
kidney neoplasms - pathology (3) 3
lung neoplasms - mortality (3) 3
lymphomas (3) 3
medicine, research & experimental (3) 3
neoplasms - drug therapy (3) 3
practice guidelines as topic (3) 3
receptor, epidermal growth factor - antagonists & inhibitors (3) 3
renal cell carcinoma (3) 3
review (3) 3
review article (3) 3
risk (3) 3
signal transduction - genetics (3) 3
spain (3) 3
trends (3) 3
tyrosine (3) 3
activating mutations (2) 2
adverse events (2) 2
afatinib (2) 2
algorithms (2) 2
analysis (2) 2
angiogenesis inhibitors - therapeutic use (2) 2
anopheles (2) 2
antibodies (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
bcl-2-like protein 11 (2) 2
beta-catenin (2) 2
brca1 (2) 2
breast cancer (2) 2
breast-cancer (2) 2
carbohydrates (2) 2
carboplatin (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 10, pp. 958 - 967
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2014, Volume 9, Issue 9, p. e107200
Journal Article
International Journal of Endocrinology, ISSN 1687-8337, 2010, Volume 2010, pp. 1 - 14
Sugars, primarily glucose and fructose, are the main energy source of cells. Because of their hydrophilic nature, cells use a number of transporter proteins to... 
RAT SKELETAL-MUSCLE | HEXOSE TRANSPORTER | HUMAN BRAIN-TUMORS | GLUCOSE-TRANSPORTER-1 EXPRESSION | DIFFERENTIAL EXPRESSION | SUBCELLULAR-DISTRIBUTION | ENDOCRINOLOGY & METABOLISM | GENE-EXPRESSION | PRIMARY LUNG CANCERS | HUMAN BREAST-CANCER | RESPONSIVE GLUCOSE-TRANSPORTER | Review
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 21, pp. 2027 - 2039
In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity... 
MEDICINE, GENERAL & INTERNAL | CERITINIB | EML4-ALK FUSION GENE | RESISTANCE | OPEN-LABEL | KINASE INHIBITOR | SINGLE-ARM | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Organophosphorus Compounds - adverse effects | Crizotinib - therapeutic use | Lung Neoplasms - chemistry | Anaplastic Lymphoma Kinase - analysis | Kaplan-Meier Estimate | Organophosphorus Compounds - therapeutic use | Crizotinib - adverse effects | Pyrimidines - therapeutic use | Progression-Free Survival | Pyrimidines - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Crizotinib | Cancer patients | Safety and security measures | Development and progression | Dosage and administration | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Nuclear magnetic resonance--NMR | Medical imaging | Statistical analysis | Lung cancer | Non-small cell lung carcinoma | Metastasis | Radiation therapy | Lymphoma | Cancer therapies | Chemotherapy | Technical communication | Mutation | Protein-tyrosine kinase | Drug dosages | Pharmaceuticals
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 12/2010, Volume 8, Issue 1, pp. 135 - 135
Journal Article
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2011, Volume 10, Issue 12, pp. 2215 - 2223
Journal Article
European Journal of Cancer Care, ISSN 0961-5423, 01/2019, Volume 28, Issue 1, pp. e12941 - n/a
Journal Article